

LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i> Sheet 1 of 1	ATTY. DOCKET NO.:	APPLICATION NO.:
	81408-4400	10/734,661
	APPLICANT:	
	Avner YAYON et al.	
	FILING DATE:	GROUP:
	December 15, 2003	1643

U.S. PATENT DOCUMENTS

*EXAMINE R INITIAL	CITE NO.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1	2004-305221 English Abstract	11/2004	JP			X	

NON-PATENT DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	C1	A-L Delezoide et al. "Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses", Human Molecular Genetics, 1997, Vol. 6, No. 11:1899-1906						
	C2	P. A. Brittis et al. "Fibroblast Growth Factor Receptor Function is required for the Orderly Projection of Ganglion Cell Axons in the Developing Mammalian Retina", Molecular and Cellular Neuroscience 8, 5:120-128 (1996)						
	C3	K. Keegan et al., "Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3", Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1095-9						
	C4	R. Shiang et al., "Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia", Cell. 1994 Jul 29;78(2):335-42.						
	C5	S. Trudel et al., "The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells", Blood. 2006 May 15;107(10):4039-46. Epub 2006 Feb 7.						

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPPE 609**. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.